Overview

This trial is active, not recruiting.

Conditions adenocarcinoma, adenocarcinoma, mucinous, carcinoma, neoplasms, glandular and epithelial, neoplasms by histologic type, neoplasms, neoplasms, cystic, mucinous, and serous, colorectal neoplasms, intestinal neoplasms, gastrointestinal neoplasms, digestive system neoplasms, neoplasms by site, digestive system diseases, gastrointestinal diseases, intestinal diseases, rectal diseases
Sponsor Royal Marsden NHS Foundation Trust
Collaborator Pelican Cancer Foundation (www.pelicancancer.org)
Start date September 2007
End date March 2016
Trial size 542 participants
Trial identifier NCT02005965, CCR2943

Summary

The MERCURY Study demonstrated the accuracy, feasibility and reproducibility of Magnetic Resonance Imaging (MRI) to stage rectal cancer in a prospective, multidisciplinary, multi-centre study. However, there were differences in patient outcome, dependent upon the position of the tumour in the rectum and its height above the anal verge. Whilst the outcome was excellent for patients who underwent an anterior resection, the outcome, based upon margin involvement and quality of the specimen, was poor for patients who underwent an abdomino-perineal excision for low rectal cancer.

It is proposed that accurate MRI staging pre-operatively will allow the correct patients to receive neo-adjuvant chemoradiotherapy (CRT), and also pre-warn the surgeons if the resection margins appear threatened so that the operation can be modified to take this into account. The primary aims of the Low Rectal Cancer Study (MERCURY II) are to assess the rate of CRM positivity rate in low rectal cancer and to assess the difference in global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Low Rectal Cancer defined on MRI as a cancer within 6cm of the anal verge

Primary Outcomes

Measure
To assess the rate of CRM positivity rate in low rectal cancer.
time frame: 4 years
To compare global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation.
time frame: 8 years

Secondary Outcomes

Measure
To compare patient reported outcomes in patients according to plane of surgery with or without sphincter preservation.
time frame: 8 years
Analysis of the clinical and radiological factors influencing the decision by surgeons to carry out Anterior Resections, APE or extralevator APE.
time frame: 8 years
Comparison of time to local recurrence, disease-free and overall survival between patients undergoing different types of surgery.
time frame: 8 years
Comparison of imaging and pathology staging assessment, patient characteristics and complication rates, between different types of surgery and surgical approaches.
time frame: 8 years
Investigation of potential associations between imaging and pathology assessment of radial and distal margins, neo-adjuvant chemoradiotherapy, perineal complications and sphincter preservation rates.
time frame: 8 years
Investigation of potential association between length of operation with number of complications and length of post-operative ITU/HDU stay.
time frame: 8 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Ability to give informed, written consent. - Adults age 18 or over - male or female. - Recently diagnosed with biopsy-proven, primary, low rectal cancer. - No previous therapy for rectal cancer. Exclusion Criteria: - Current pregnancy, including ectopic pregnancy. - Previous pelvic/rectal malignancy (excluding carcinoma in-situ). - Previous pelvic radiotherapy. - Previous pelvic floor surgery for faecal incontinence or prolapse.

Additional Information

Official title The Low Rectal Cancer Study.
Principal investigator Gina Brown
Description The aim of this study is to reduce the positive margin rate of 30% to around 15%. The study is an international multicentre, prospective, observational study, whereby patients with biopsy-proven low-rectal cancer (lower edge of the tumour < 6cms from the anal verge on MRI), will be recruited from participating centres, having given informed, written consent. Data from the radiology, surgical and pathological aspects will be collected and analysed centrally at the Royal Marsden Hospital. The patient's medical records will be reviewed for five years post surgery, and the patients will also be followed up by quality of life questionnaires. This project aims to show that in low rectal cancer, improved local control and survival can be achieved through a reduction in the involved CRM rates by MRI-planned surgery and selective pre-operative therapy. It also aims to assess the ability to predict disease recurrence and to provide an assessment of disease-free survival and overall survival.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Royal Marsden NHS Foundation Trust.